383 results
8-K
EX-99.1
LXRX
Lexicon Pharmaceuticals Inc
2 May 24
Lexicon Pharmaceuticals Reports First Quarter 2024
4:07pm
(sotagliflozin) is an oral inhibitor of two proteins responsible for glucose regulation known as sodium-glucose cotransporter types 2 and 1 (SGLT2 and SGLT1 … ). SGLT2 is responsible for glucose and sodium reabsorption by the kidney and SGLT1 is responsible for glucose and sodium absorption in the gastrointestinal
8-K
EX-99.1
h2xeuv0v2x4gumm1
11 Mar 24
Lexicon Pharmaceuticals Reports Fourth Quarter 2023
7:26am
8-K
EX-10.1
1ev62q0wdglsicm0c
11 Mar 24
Lexicon Pharmaceuticals Reports Fourth Quarter 2023
7:26am
424B5
jwx pj1y5cm
29 Dec 23
Prospectus supplement for primary offering
5:27pm
8-K
EX-99.1
xbn4iw53bo9t
8 Nov 23
Lexicon Pharmaceuticals Reports Third Quarter 2023
7:22am
8-K
EX-99.1
9fmn4y98t a5
3 Aug 23
Lexicon Pharmaceuticals Reports Second Quarter 2023
4:08pm
8-K
EX-99.1
qhwksvbhi
31 Jul 23
Lexicon Elects Diane E. Sullivan to Board of Directors
4:02pm
8-K
EX-1.1
56vsbt3st0avlc1arf2z
2 Jun 23
Lexicon Announces Pricing of $125 Million Public Offering and Concurrent Private Placement
4:31pm
424B5
rthlsxb6ws47kpk37
1 Jun 23
Prospectus supplement for primary offering
9:08pm